[go: up one dir, main page]

RU2018102078A - Комбинированная терапия противоопухолевым алкалоидом - Google Patents

Комбинированная терапия противоопухолевым алкалоидом Download PDF

Info

Publication number
RU2018102078A
RU2018102078A RU2018102078A RU2018102078A RU2018102078A RU 2018102078 A RU2018102078 A RU 2018102078A RU 2018102078 A RU2018102078 A RU 2018102078A RU 2018102078 A RU2018102078 A RU 2018102078A RU 2018102078 A RU2018102078 A RU 2018102078A
Authority
RU
Russia
Prior art keywords
cancer
synergistic combination
combination according
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
RU2018102078A
Other languages
English (en)
Other versions
RU2018102078A3 (ru
RU2757373C2 (ru
Inventor
ОКАНЬЯ Виктория МОНЕО
НУНЬЕС Хема САНТАМАРИЯ
ФЕРНАНДЕС Луис Франсиско ГАРСИА
Карлос Мария ГАЛМАРИНИ
НАВАРРО Мария Хосе ГИЛЬЕН
МАРИН Пабло Мануэль АВИЛЕС
Original Assignee
Фарма Мар, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарма Мар, С.А. filed Critical Фарма Мар, С.А.
Publication of RU2018102078A publication Critical patent/RU2018102078A/ru
Publication of RU2018102078A3 publication Critical patent/RU2018102078A3/ru
Application granted granted Critical
Publication of RU2757373C2 publication Critical patent/RU2757373C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Claims (12)

1. Фармацевтическая синергическая комбинация для лечения рака, содержащая терапевтически эффективное количество РМ01183 или его фармацевтически приемлемой соли и терапевтически эффективное количество ингибитора митоза.
2. Синергическая комбинация по п. 1, где рак, подлежащий лечению, выбран из рака легкого, саркомы, злокачественной меланомы, рака мочевого пузыря, рака предстательной железы, рака поджелудочной железы, рака щитовидной железы, рака желудка, рака яичника, гепатомы, рака молочной железы, колоректального рака, рака почки, рака пищевода, нейробластомы, рака головного мозга, рака шейки матки, анального рака, рака яичка, лейкоза, множественной миеломы и лимфомы.
3. Синергическая комбинация по п. 2, где рак, подлежащий лечению, выбран из рака легкого, саркомы, рака предстательной железы, рака поджелудочной железы, рака желудка, рака яичника, гепатомы, рака молочной железы, колоректального рака, рака почки и рака головного мозга.
4. Синергическая комбинация по п. 1, где РМ01183 или его фармацевтически приемлемая соль и ингибитор митоза
5. Синергическая комбинация по п. 1, где РМ01183 или его фармацевтически приемлемая соль и ингибитор митоза представлены в форме отдельных лекарственных средств для введения в одно и то же время или в разное время.
6. Синергическая комбинация по п. 5, где РМ01183 или его фармацевтически приемлемая соль и ингибитор митоза представлены в форме отдельных лекарственных средств для введения в разное время.
7. Синергическая комбинация по п. 1, где ингибитор митоза выбран из паклитаксела, доцетаксела, винбластина, винкристина, виндезина и винорелбина.
8. Синергическая комбинация по п. 7, где ингибитор митоза выбран из паклитаксела, доцетаксела, винкристина и винорелбина.
9. Синергическая комбинация по п. 8, где ингибитор митоза представляет собой паклитаксел.
10. Способ лечения рака, включающий введение пациенту, который нуждается в указанном лечении, синергической комбинации по любому из пп. 1-9.
11. Применение синергической комбинации по любому из пп. 1-9 для лечения рака.
12. Применение синергической комбинации по любому из пп. 1-9 в производстве лекарственного средства для лечения рака.
RU2018102078A 2010-11-12 2018-01-19 Комбинированная терапия противоопухолевым алкалоидом RU2757373C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10382300 2010-11-12
EP10382300.1 2010-11-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2016144668A Division RU2743643C2 (ru) 2010-11-12 2011-11-11 Комбинированная терапия противоопухолевым алкалоидом

Publications (3)

Publication Number Publication Date
RU2018102078A true RU2018102078A (ru) 2019-07-19
RU2018102078A3 RU2018102078A3 (ru) 2021-04-20
RU2757373C2 RU2757373C2 (ru) 2021-10-14

Family

ID=44936282

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2013126630/15A RU2605335C2 (ru) 2010-11-12 2011-11-11 Комбинированная терапия противоопухолевым алкалоидом
RU2016144668A RU2743643C2 (ru) 2010-11-12 2011-11-11 Комбинированная терапия противоопухолевым алкалоидом
RU2018102080A RU2767664C2 (ru) 2010-11-12 2018-01-19 Комбинированная терапия противоопухолевым алкалоидом
RU2018102078A RU2757373C2 (ru) 2010-11-12 2018-01-19 Комбинированная терапия противоопухолевым алкалоидом

Family Applications Before (3)

Application Number Title Priority Date Filing Date
RU2013126630/15A RU2605335C2 (ru) 2010-11-12 2011-11-11 Комбинированная терапия противоопухолевым алкалоидом
RU2016144668A RU2743643C2 (ru) 2010-11-12 2011-11-11 Комбинированная терапия противоопухолевым алкалоидом
RU2018102080A RU2767664C2 (ru) 2010-11-12 2018-01-19 Комбинированная терапия противоопухолевым алкалоидом

Country Status (24)

Country Link
US (5) US20130266666A1 (ru)
EP (6) EP2786755A3 (ru)
JP (4) JP6382516B2 (ru)
KR (9) KR20160088956A (ru)
CN (3) CN105664165A (ru)
AU (4) AU2011328004C1 (ru)
BR (4) BR122017028568B1 (ru)
CA (4) CA2995033C (ru)
CY (4) CY1117466T1 (ru)
DK (4) DK2637663T3 (ru)
ES (4) ES2569180T3 (ru)
HK (1) HK1202422A1 (ru)
HR (4) HRP20160361T1 (ru)
HU (4) HUE049389T2 (ru)
LT (3) LT2786756T (ru)
ME (3) ME02395B (ru)
PL (4) PL2786756T3 (ru)
PT (3) PT2786756T (ru)
RS (4) RS54648B1 (ru)
RU (4) RU2605335C2 (ru)
SI (4) SI2786756T1 (ru)
SM (4) SMT201900190T1 (ru)
TR (2) TR201904459T4 (ru)
WO (1) WO2012062920A1 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
JP6382516B2 (ja) * 2010-11-12 2018-08-29 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍アルカロイドを用いる、組み合わせの治療法
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
CA2975223C (en) * 2015-01-30 2021-08-24 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
JP7022066B2 (ja) * 2016-01-11 2022-02-17 シンデブルックス，インコーポレイティド 代謝機能不全によって引き起こされる腫瘍の治療
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
JP2022512826A (ja) 2018-10-26 2022-02-07 シンデブルックス，インコーポレイティド ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用
CA3148690A1 (en) * 2019-09-03 2021-03-11 Ioannis METAXAS Lurbinectedin in the treatment of malignant mesothelioma
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
MA56827B2 (fr) 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CR20220289A (es) * 2019-11-21 2022-10-27 Pharma Mar Sa Métodos de tratamiento del cáncer de pulmón de células pequeñas con formulaciones de lurbinectedina
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A4 (en) 2020-04-24 2025-04-09 Sf Biotech Laboratuvar Danismanlik Anonim Sirketi Method for producing particles of bacteriophages of the genus levivirus
JP7669053B2 (ja) * 2020-07-01 2025-04-28 ニュー キャンサー キュア－バイオ カンパニー リミテッド ３－ケトアシルｃｏａタイオレース阻害剤とカルニチンアシルカルニチンキャリア阻害剤を含む癌の予防または治療のための医薬組成物
CN114470216B (zh) * 2020-10-23 2024-08-06 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN113633631B (zh) * 2021-06-17 2022-08-09 中国医学科学院医药生物技术研究所 米铂脂质体在抗耐药性肿瘤的应用
CN115246846B (zh) * 2021-11-19 2024-10-01 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof
WO2024188978A1 (en) * 2023-03-10 2024-09-19 Pharma Mar, S.A. Lurbinectedin as mcl-1 inhibitor and combinations thereof for use in treating cancer
EP4563149A1 (en) * 2023-11-30 2025-06-04 Pharma Mar, S.A. Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers
WO2025228597A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of compound ia and a topoisomerase i inhibitor in the treatment of cancer
WO2025228596A1 (en) 2024-04-30 2025-11-06 Pharma Mar, S.A. Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3774435D1 (de) 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
IL138856A0 (en) 1998-04-06 2001-10-31 Univ Illinois Semi-synthetic ecteinascidins
CA2331593C (en) 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
JP2003520801A (ja) 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
CA2406080C (en) 2000-04-12 2011-11-29 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP4391083B2 (ja) * 2000-11-06 2009-12-24 ファルマ・マール・ソシエダード・アノニマ 効果的な抗腫瘍治療
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
KR100668539B1 (ko) 2002-08-19 2007-01-16 화이자 프로덕츠 인크. 과증식성 질환에 대한 조합요법
CA2501089C (en) 2002-10-18 2012-07-17 Pharma Mar, S.A.U. 4-methylhexanoic kahalaide f compound
FR2856688B1 (fr) * 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
DK1689404T3 (da) * 2003-11-13 2009-01-26 Pharma Mar Sau Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005049030A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
CA2566156A1 (en) * 2004-05-28 2005-12-08 Pfizer Products Inc. Method for treating abnormal cell growth
SI1658848T1 (sl) 2004-10-29 2007-12-31 Pharma Mar Sa Formulacije vsebujoäśe ekteinascidin in disaharid
ATE531371T1 (de) 2004-12-15 2011-11-15 Novartis Ag Kombinationen von therapeutischen wirkstoffen zur krebsbehandlung
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
KR20140101014A (ko) * 2006-02-28 2014-08-18 파르마 마르 에스.에이. 개선된 항종양 치료
KR20110025178A (ko) * 2008-05-16 2011-03-09 파르마 마르 에스.에이. Ｐｍ00104 및 다른 항종양제를 이용한 복합 치료법
JP6382516B2 (ja) * 2010-11-12 2018-08-29 ファルマ・マール・ソシエダード・アノニマ 抗腫瘍アルカロイドを用いる、組み合わせの治療法

Also Published As

Publication number Publication date
AU2011328004C1 (en) 2017-01-19
CA2995025A1 (en) 2012-05-18
CY1121504T1 (el) 2020-05-29
RS58608B1 (sr) 2019-05-31
KR20160088956A (ko) 2016-07-26
AU2017276157B2 (en) 2019-03-07
CA2995033C (en) 2020-04-28
RS60236B1 (sr) 2020-06-30
HK1202423A1 (en) 2015-10-02
CN103282037A (zh) 2013-09-04
LT2786756T (lt) 2020-05-11
RU2018102078A3 (ru) 2021-04-20
ME03501B (me) 2020-04-20
JP2016138133A (ja) 2016-08-04
AU2017276155B2 (en) 2019-03-07
ES2719091T3 (es) 2019-07-08
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
CA2817420C (en) 2019-09-24
KR20130140071A (ko) 2013-12-23
JP6724055B2 (ja) 2020-07-15
SI2786754T1 (sl) 2019-05-31
CN106860870B (zh) 2020-03-31
BR112013011480A2 (pt) 2016-08-09
BR122017028570B1 (pt) 2022-03-03
KR102452022B1 (ko) 2022-10-06
SI2786753T1 (sl) 2019-05-31
TR201904459T4 (tr) 2019-05-21
PL2786756T3 (pl) 2020-07-13
TR201903859T4 (tr) 2019-04-22
US20180078551A1 (en) 2018-03-22
US20230404999A1 (en) 2023-12-21
CN106860870A (zh) 2017-06-20
HRP20200696T1 (hr) 2020-07-24
JP6724056B2 (ja) 2020-07-15
US11590129B2 (en) 2023-02-28
CA2817420A1 (en) 2012-05-18
RU2018102080A (ru) 2019-07-19
SI2786756T1 (sl) 2020-07-31
EP2786756A3 (en) 2014-10-29
AU2011328004B2 (en) 2016-07-14
JP2018100302A (ja) 2018-06-28
HRP20190565T1 (hr) 2019-05-17
RU2018102080A3 (ru) 2021-04-12
WO2012062920A1 (en) 2012-05-18
EP2637663A1 (en) 2013-09-18
BR112013011480B1 (pt) 2022-03-22
LT2786754T (lt) 2019-04-10
PL2637663T3 (pl) 2016-08-31
KR102247982B1 (ko) 2021-05-04
DK2786754T3 (en) 2019-04-15
HK1202419A1 (en) 2015-10-02
HK1202422A1 (en) 2015-10-02
US20130266666A1 (en) 2013-10-10
PL2786754T3 (pl) 2019-07-31
CA2995018A1 (en) 2012-05-18
US20180078550A1 (en) 2018-03-22
KR102301175B1 (ko) 2021-09-10
JP2018100303A (ja) 2018-06-28
KR20170124641A (ko) 2017-11-10
PT2786754T (pt) 2019-04-24
EP2786753B1 (en) 2019-01-09
SMT201600112B (it) 2016-07-01
EP2786755A2 (en) 2014-10-08
JP6382516B2 (ja) 2018-08-29
EP2786756B1 (en) 2020-03-11
EP2786754A3 (en) 2014-10-29
KR20210046853A (ko) 2021-04-28
HRP20190554T1 (hr) 2019-05-03
CY1121501T1 (el) 2020-05-29
EP2786754B1 (en) 2019-01-09
AU2017276157A1 (en) 2018-01-04
RU2013126630A (ru) 2014-12-20
KR20170057472A (ko) 2017-05-24
HUE049389T2 (hu) 2020-09-28
ES2790414T3 (es) 2020-10-27
RU2016144668A3 (ru) 2020-03-25
ES2719052T3 (es) 2019-07-08
CN103282037B (zh) 2017-04-05
PL2786753T3 (pl) 2019-09-30
CA2995025C (en) 2020-04-28
KR20170096065A (ko) 2017-08-23
SMT202000211T1 (it) 2020-05-08
SMT201900190T1 (it) 2019-05-10
CY1117466T1 (el) 2017-04-26
AU2017276155A1 (en) 2018-01-04
EP2637663B1 (en) 2016-02-24
DK2786756T3 (en) 2020-04-27
HUE042802T2 (hu) 2019-07-29
PT2786756T (pt) 2020-05-07
AU2011328004A1 (en) 2013-05-30
CA2995033A1 (en) 2012-05-18
CA2995018C (en) 2021-04-20
EP3666275A2 (en) 2020-06-17
PT2786753T (pt) 2019-04-24
EP2786755A3 (en) 2014-10-29
ME02395B (me) 2016-09-20
DK2637663T3 (en) 2016-04-18
RU2757373C2 (ru) 2021-10-14
RS58609B1 (sr) 2019-05-31
BR112013011480A8 (pt) 2018-01-02
BR122017028566B1 (pt) 2022-03-03
DK2786753T3 (en) 2019-04-15
KR101716804B1 (ko) 2017-03-15
HK1188572A1 (zh) 2014-05-09
ME03408B (me) 2020-01-20
CN105664165A (zh) 2016-06-15
HUE042801T2 (hu) 2019-07-29
KR20170096224A (ko) 2017-08-23
ES2569180T3 (es) 2016-05-09
HUE027516T2 (en) 2016-10-28
EP2786753A2 (en) 2014-10-08
JP2013542241A (ja) 2013-11-21
EP2786754A2 (en) 2014-10-08
RU2016144668A (ru) 2018-12-18
US20180008602A1 (en) 2018-01-11
EP2786756A2 (en) 2014-10-08
AU2016200191B2 (en) 2018-01-18
JP6723815B2 (ja) 2020-07-15
RU2767664C2 (ru) 2022-03-18
SI2637663T1 (sl) 2016-05-31
KR20190130078A (ko) 2019-11-20
CY1122904T1 (el) 2021-10-29
RU2743643C2 (ru) 2021-02-20
RS54648B1 (sr) 2016-08-31
SMT201900186T1 (it) 2019-05-10
RU2605335C2 (ru) 2016-12-20
BR122017028568B1 (pt) 2022-03-03
AU2016200191A1 (en) 2016-02-04
EP3666275A3 (en) 2020-09-09
HK1202421A1 (en) 2015-10-02

Similar Documents

Publication Publication Date Title
RU2018102078A (ru) Комбинированная терапия противоопухолевым алкалоидом
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
RU2018138627A (ru) Комбинированная терапия ингибиторами notch и cdk4/6 для лечения рака
PH12016502354A1 (en) Pharmaceutical composition
NZ746054A (en) Methods of treating cancer
JP2012082234A5 (ru)
TR201807411T4 (tr) DNA-PK inhibitörleri.
JP2016536352A5 (ru)
JP2016528162A5 (ru)
RU2018138626A (ru) Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
EA201000127A1 (ru) Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака
SA515370134B1 (ar) تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي
RU2010140890A (ru) Улучшенные способы противоопухолевого лечения
NZ589269A (en) Combination therapy with an antitumor alkaloid
TW201613589A (en) Combination methods for treating cancers
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
HRP20201819T1 (hr) Farmaceutski pripravak za liječenje raka koji sadrži laktatnu metalnu sol
RU2012148767A (ru) Способы лечения метотрексатустойчивых расстройств 10-пропаргил-10-деазааминоптерином
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
NI201100192A (es) Combinación antitumoral que compprende cabazitaxel y capecitabina
RU2015156221A (ru) Фармацевтические комбинация ингибитора pi3k и средства, дестабилизирующего микротрубочки
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
WO2014115859A3 (ja) 分子標的併用腫瘍治療・予防薬
RU2010119922A (ru) Усовершенствованное противоопухолевое лечение